Covid 19
Covaxin works against UK strain, will release study by January 10: Bharat Biotech CMD
CMD Dr Krishna Ella, addressing a virtual press conference, said: "We have taken 3-4 strains and studied it. It will come in publication on Medrevix on January 10. In a week's time, our confirmative data would come." Covaxin, India's indigenous COVID-19 vaccine by Bharat Biotech, is developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). The inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) bio-containment facility.
Covaxin generated excellent safety data, says Bharat Biotech
Covaxin is a highly purified and inactivated 2 dose SARS-CoV2 vaccine, manufactured in a Vero cell manufacturing platform with an excellent safety track record of more than 300 million doses, the Hyderabad-based company said in a statement.
500-600 Covid centres in phase 1 of vaccination: Delhi government
Delhi Health Minister Satyendar Jain made the announcement during a press conference while commenting on the protocol that will be followed for the rollout of the vaccine. The minister said "500-600 Covid centres will be set up in the first phase and it will be further escalated to 1,000. Storage facilities have been made. Ultimately, 1,000 centres will be there."
Covishield and Covaxin: Know price, other details of Covid-19 vaccines approved by DCGI
The vaccines are being hailed as a win for the country’s medical development as both of them have indigenous roots. Covaxin, developed and produced by Bharat Biotech is India’s premier solution for COVID-19 whereas, Covishield is developed by Oxford University and AstraZeneca has been manufactured and tested by Serum Institute of India (SII).
A decisive turning point: PM Modi on Covid vaccine approval
Prime Minister's remarks came after the Drugs Controller General of India Dr. V.G. Somani announced that the CDSCO has decided to accept the recommendations of the Subject Expert Committee and accordingly, vaccine of Serum and Bharat Biotech are being approved for restricted use in emergency situation after adequate examination.
Covid-19 Vaccination: India approves Oxford's COVISHIELD and indigenous COVAXIN
This is a major relief for India which has the second-highest number of infections in the world, after the US. The Central government plans to vaccinate nearly 30 crore people in the first phase of drive in the next six to eight months. The vaccine will be first offered to one crore healthcare workers, along with two crore frontline and essential workers and 27 crores elderly, mostly above the age of 50 years with co-morbidities.
40 patients suffering from new Covid strain admitted to LNJP
Talking about the current situation in the capital, Delhi's Health Minister Satyendar Jain said on Saturday that the positivity rate in Delhi was 0.73 per cent and is steadily declining as only 585 new cases were reported in Delhi on Friday. "We hope that the number of new cases in Delhi remain below 500," he added.
Bharat Biotech recruits 23,000 volunteers for Phase III trials of Covaxin
The phase-III human clinical trials of Covaxin began mid-November, targeting 26,000 volunteers across India. This is India's first and only phase III efficacy study for a Covid-19 vaccine, and the largest phase III efficacy trial ever conducted for any vaccine in India, the Hyderabad-based company said.
Self-paid RT-PCR test mandatory for UK flyers from January 8
Flight services between the two countries were suspended on December 22 in the wake of a more infectious coronavirus strain found in UK's population. Th services will resume on January 6. This strain has so far been detected in over 29 travellers in India. According to the standard operating procedure issued by the health ministry, those travelling between January 8 and 31, would be mandatorily subjected to self-paid RT-PCR tests on arrival at the Indian airports concerned.
Covid-19 Vaccination: India witnesses dry run to test systems
On the Centre's directive, Delhi, Punjab and Haryana along with Andhra Pradesh, Assam and Gujarat were among many states and UTs who conducted a dry run for Covid-19 vaccination earlier in the day, aimed at testing the laid out mechanisms for the vaccination roll-out in the health system. The Centre had directed earlier to conduct a dry run by all state and UTs on January 2 to test the linkages between planning and implementation, and to identify the challenges.
Advertisement